An update on the role of SMARCA4 deficiency in gynecological neoplasms: how and where

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• SMARCA4, encoding the BRG1 protein, is vital for the SWI/SNF chromatin remodeling complex.
• SMARCA4 alterations are linked to aggressive gynecological cancers, including SCCOHT, uterine sarcomas, and endometrial carcinomas.
• The role of SMARCA4 in tumorigenesis is an evolving area of research.

Purpose of the Study:

• To review the current understanding of SMARCA4 deficiency in gynecological cancers.
• To discuss the morphological and immunophenotypic features of SMARCA4-deficient entities.
• To highlight clinical implications and potential targeted therapies for these tumors.

Main Methods:

• Literature review of studies on SMARCA4 in gynecological neoplasms.
• Analysis of morphological and immunophenotypic characteristics.
• Synthesis of information on clinical outcomes and therapeutic strategies.

Main Results:

• SMARCA4 deficiency is a hallmark of specific aggressive gynecological cancers.
• Distinct morphological and immunophenotypic profiles characterize these SMARCA4-deficient tumors.
• Targeting SMARCA4 alterations presents a promising therapeutic avenue.

Conclusions:

• SMARCA4 deficiency plays a critical role in the pathogenesis of aggressive gynecological cancers.
• Accurate diagnosis and understanding of SMARCA4-deficient tumors are essential for effective treatment.
• Further research into SMARCA4's function and vulnerabilities can improve patient outcomes.